Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies

Vaccine

Volumn 33, Issue 14, 2015, Pages 1739-1747

  Roos, Anna ^a,b   Roozendaal, Ramon ^a,b   Theeuwsen, Jessica ^a,b   Riahi, Sarra ^a,b   Vaneman, Joost ^a,b   Tolboom, Jeroen ^a,b   Dekking, Liesbeth ^a,b   Koudstaal, Wouter ^a,b   Goudsmit, Jaap ^a,b   Radošević, Katarina ^a,c  

^a CRUCELL HOLLAND BV   (Netherlands)

^b Janssen Research and Development   (Netherlands)

^c SANOFI   (France)

Author keywords

Correlate of protection; Heterosubtypic protection; Influenza challenge model; Mice; Seasonal influenza vaccine; Serum transfer

Indexed keywords

EPITOPE; HEMAGGLUTININ; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; SEASONAL INFLUENZA VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FEMALE; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CROSS PROTECTION; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); ORTHOMYXOVIRIDAE INFECTIONS; SEASON; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SEASONS;

EID: 84925244051     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.070     Document Type: Article

References (50)

1. WHO fact sheet, [08.09.14]. http://www.who.int/mediacentre/factsheets/fs211/en/.
2. Belshe R.B., Toback S.L., Yi T., Ambrose C.S. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respir Viruses 2010, 4:141-145. 10.1111/j.1750-2659.2009.00124.x.
3. Quadrivalent Influenza Vaccine, [05.09.14]. http://www.cdc.gov/flu/protect/vaccine/quadrivalent.htm.
4. Hannoun C., Megas F., Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004, 103:133-138. 10.1016/j.virusres.2004.02.025.
5. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70:767-777.
6. Wood J.M., Levandowski R.A. The influenza vaccine licensing process. Vaccine 2003, 21:1786-1788.
7. Wiley D.C., Wilson I.A., Skehel J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981, 289:373-378.
8. Bizebard T., Gigant B., Rigolet P., Rasmussen B., Diat O., Bosecke P., et al. Structure of influenza virus haemagglutinin complexed with a neutralizing antibody. Nature 1995, 376:92-94. 10.1038/376092a0.
9. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531-569. 10.1146/annurev.biochem.69.1.531.
10. Barbey-Martin C., Gigant B., Bizebard T., Calder L.J., Wharton S.A., Skehel J.J., et al. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology 2002, 294:70-74. 10.1006/viro.2001.1320.
11. Hirst G.K. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med 1942, 75:49-64.
12. Salk J.E. A simplified procedure for titrating hemagglutinating capacity of influenza-virus and the corresponding antibody. J Immunol 1944, 49:87-98.
13. Guidance for industry, [08.09.14). http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf.
14. Co M.D., Orphin L., Cruz J., Pazoles P., Green K.M., Potts J., et al. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 2009, 27:319-327. 10.1016/j.vaccine.2008.09.092.
15. Regulations of seasonal influenza vaccine,. http://www.who.int/biologicals/publications/trs/areas/vaccines/influenza/ANNEX%203%20InfluenzaP99-134.pdf?ua=1.
16. Drake J.W. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 1993, 90:4171-4175.
17. Knossow M., Skehel J.J. Variation and infectivity neutralization in influenza. Immunology 2006, 119:1-7. 10.1111/j.1365-2567.2006.02421.x.
18. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56:152-179.
19. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21:1776-1779.
20. The WHO vaccine strain selection, [08.09.14]. http://www.who.int/immunization/research/meetings_workshops/Jacqueline_Katz.pdf.
21. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856. 10.1126/science.1205669.
22. Dreyfus C., Laursen N.S., Kwaks T., Zuijdgeest D., Khayat R., Ekiert D.C., et al. Highly conserved protective epitopes on influenza B viruses. Science 2012, 337:1343-1348. 10.1126/science.1222908.
23. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251. 10.1126/science.1171491.
24. Ekiert D.C., Friesen R.H., Bhabha G., Kwaks T., Jongeneelen M., Yu W., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333:843-850. 10.1126/science.1204839.
25. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273. 10.1038/nsmb.1566.
26. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008, 3:e3942. 10.1371/journal.pone.0003942.
27. Krammer F., Cox R.J. The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines. Expert Rev Vaccines 2013, 12:1369-1372. 10.1586/14760584.2013.850036.
28. Bommakanti G., Lu X., Citron M.P., Najar T.A., Heidecker G.J., ter Meulen J., et al. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 2012, 86:13434-13444. 10.1128/JVI.01429-12.
29. Ohshima N., Kubota-Koketsu R., Iba Y., Okuno Y., Kurosawa Y. Two types of antibodies are induced by vaccination with A/California/2009pdm virus: Binding near the sialic acid-binding pocket and neutralizing both H1N1 and H5N1 viruses. PLoS ONE 2014, 9:e87305. 10.1371/journal.pone.0087305.
30. Marcelin G., Sandbulte M.R., Webby R.J. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol 2012, 22:267-279. 10.1002/rmv.1713.
31. Hashem A.M., Van Domselaar G., Li C., Wang J., She Y.M., Cyr T.D., et al. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun 2010, 403:247-251. 10.1016/j.bbrc.2010.11.030.
32. van Maurik A., Sabarth N., Dacho H.S., Bruhl P., Schwendinger M., Crowe B.A., et al. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. Vaccine 2010, 28:1778-1785. 10.1016/j.vaccine.2009.12.008.
33. Rockman S., Brown L.E., Barr I.G., Gilbertson B., Lowther S., Kachurin A., et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol 2013, 87:3053-3061. 10.1128/JVI. 02434-12.
34. Ding H., Tsai C., Zhou F., Buchy P., Deubel V., Zhou P. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus. PLoS ONE 2011, 6:e17821. 10.1371/journal.pone.0017821.
35. Ichinohe T., Tamura S., Kawaguchi A., Ninomiya A., Imai M., Itamura S., et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 2007, 196:1313-1320. 10.1086/521304.
36. Song J.M., Van Rooijen N., Bozja J., Compans R.W., Kang S.M. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci USA 2011, 108:757-761. 10.1073/pnas.1012199108.
37. Tricco A.C., Chit A., Soobiah C., Hallett D., Meier G., Chen M.S., et al. Comparing influenza vaccine efficacy against mismatched and matched strains: A systematic review and meta-analysis. BMC Med 2013, 11:153. 10.1186/1741-7015-11-153.
38. Gioia C., Castilletti C., Tempestilli M., Piacentini P., Bordi L., Chiappini R., et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008, 14:121-128. 10.3201/eid1401.061283.
39. Roozendaal R., Tolboom J., Roos A., Riahi S., Theeuwsen J., Bujny M.V., et al. Transient humoral protection against H5N1 challenge after seasonal influenza vaccination of humans. PLoS ONE 2014, 9:e103550. 10.1371/journal.pone.0103550.
40. Dilillo D.J., Tan G.S., Palese P., Ravetch J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 2014, 20:143-151. 10.1038/nm.3443.
41. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007, 4:e59. 10.1371/journal.pmed.0040059.
42. Lamere M.W., Moquin A., Misra R.S., Blair R.J., Haynes L., Randall T.D., et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 2011, 85:5027-5035. 10.1128/JVI. 00150-11.
43. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983, 309:13-17. 10.1056/NEJM198307073090103.
44. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18:274-280. 10.1038/nm.2612.
45. Hillaire M.L., Osterhaus A.D., Rimmelzwaan G.F. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011, 2011:939860. 10.1155/2011/939860.
46. Terajima M., Babon J.A., Co M.D., Ennis F.A. Cross-reactive human B cell and T cell epitopes between influenza A and B viruses. Virol J 2013, 10:244. 10.1186/1743-422X-10-244.
47. Budimir N., Huckriede F.A., Meijerhof T., Boon L., Gostick E., Price D.A., et al. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS ONE 2012, 7:e30898. 10.1371/journal.pone.0030898.
48. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23:5404-5410. 10.1016/j.vaccine.2005.04.047.
49. Price G.E., Soboleski M.R., Lo C.Y., Misplon J.A., Pappas C., Houser K.V., et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27:6512-6521. 10.1016/j.vaccine.2009.08.053.
50. Sridhar S., Begom S., Bermingham A., Hoschler K., Adamson W., Carman W., et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013, 19:1305-1312. 10.1038/nm.3350.